A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Running, not enrolling · Phase 3 · Has a placebo group
Conditions studied: Obesity
In brief
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.
Key facts
- Study ID
- NCT06780449
- Run by
- Novo Nordisk A/S
- People needed
- 400
- Starts
- 2025-02-10
- Expected to finish
- 2028-10-31
- Last updated by the study team
- 2026-01-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female.
- Age above or equal to 18 years at the time of signing informed consent.
- Body mass index (BMI) greater than or equal to (>=) 35.0 kilograms per meter square (kg/m\^2).
You may not qualify if…
- Glycated haemoglobin (HbA1c) >= 6.5 percent (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
- History of type 1 or type 2 diabetes.
Where it is running
- Valley Clinical Trials — Covina, California, United States
- Diablo Clinical Research, Inc. — Walnut Creek, California, United States
- Yale University School Of Medicine — New Haven, Connecticut, United States
- East West Medical Research Institute_Honolulu — Honolulu, Hawaii, United States
- L-MARC Research Center — Louisville, Kentucky, United States
- StudyMetrix Research LLC — City of Saint Peters, Missouri, United States
- Spartanburg Medical Research — Spartanburg, South Carolina, United States
- Holston Medical Group_Bristol — Bristol, Tennessee, United States
- North Texas Endocrine Center — Dallas, Texas, United States
- Washington Cntr Weight Mgmt — Arlington, Virginia, United States
- Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie — Brussels, Belgium
- UZA - UZ Antwerpen - Department of Endocrinology — Edegem, Belgium
- UZ Leuven - Endocrinology — Leuven, Belgium
- CHU Helora - Hôpital de Mons - Site Constantinople — Mons, Belgium
- Dr. M.B. Jones Inc — Victoria, British Columbia, Canada
- Nova Scotia Health Authority — Halifax, Nova Scotia, Canada
- Premier Clinical Trial Research Network (PCTRN) — Hamilton, Ontario, Canada
- Alpha Recherche Clinique - Lebourgneuf — Québec, Canada
- Aarhus Universitetshospital, Steno Diabetes Center Aarhus — Aarhus, Denmark
- Sydvestjysk Sygehus Esbjerg - Medicinsk Endokrinologisk Ambulatorium, Forskningsenheden — Esbjerg, Denmark
- Gentofte Hospital - Center for Klinisk Metabolisk Forskning — Hellerup, Denmark
- Hvidovre Hospital Endokrinologisk forsknings afsnit 159 — Hvidovre, Denmark
- Sjællands Universitetshospital, Køge - Medicinsk Afdeling — Køge, Denmark
- ULS De Matosinhos E.P.E.- Hospital Pedro Hispano — Senhora Da Hora, Matosinhos, Matosinhos, Portugal
- APDP - Associação Protectora dos Diabéticos de Portugal — Lisbon, Portugal
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.